Aarti Drugs Buyback 2024 vs Nava Limited Buyback 2025

Comparison between Aarti Drugs Buyback 2024 and Nava Limited Buyback 2025.

Buyback Details

Aarti Drugs Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Nava Limited Buyback 2025 is a Tender Offer proposed to list at BSE, NSE.

 Aarti Drugs Ltd.Nava Ltd.
LogoAarti Drugs Buyback 2024 LogoNava Limited Buyback 2025 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹10 per share₹1 per share
Buyback Price₹900 per share₹500 per share
Issue Size6,65,000 shares72,00,000 shares
Issue Size (Amount)₹59.85 Crores₹360.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders9 Equity Shares out of every 706 Fully paid-up Equity Shares held on the Record Date.99,750
General Category for all other Eligible Shareholders5 Equity Shares out of every 744 Fully paid-up Equity Shares held on the Record Date.5,65,250
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders17 Equity Shares out of every 83 Fully paid-up Equity Shares held on the Record Date.10,80,000
General Category for all other Eligible Shareholders8 Equity Shares out of every 187 Fully paid-up Equity Shares held on the Record Date.61,20,000
RegistrarMUFG Intime India Pvt.Ltd.Kfin Technologies Ltd.
Lead ManagersInga Ventures Pvt.Ltd.Anand Rathi Advisors Ltd.
Necessity of the buyback

The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company’s management strives to increase equity shareholder's value and the Buyback would result in amongst other things:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares;
  2. The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by a reduction in the equity base, thereby leading to a long-term increase in shareholders’ value;
  3. The Buyback gives an option to the shareholders holding Equity Shares of the Company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment; and
  4. The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would be classified as Small Shareholders.

The Buyback is being undertaken for the following reasons:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding.
  2. The buyback consists of a reservation for the small shareholder. The company believes that this reservation for small shareholders would benefit many public shareholders who would be classified as "small shareholders".
  3. The buyback may help in improving financial ratios like return on equity, by reduction in the equity base, thereby leading to a long-term increase in shareholders' value.
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.

Buyback Timetable

Aarti Drugs Buyback 2024 and Nava Limited Buyback 2025 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aarti Drugs Buyback 2024 Buyback record date is Sep 05, 2024. Nava Limited Buyback 2025 Buyback record date is Feb 28, 2025.

 Aarti Drugs Ltd.Nava Ltd.
Record DateSep 05, 2024Feb 28, 2025
Offer Open DateSep 11, 2024Mar 06, 2025
Offer Closure DateSep 19, 2024Mar 12, 2025
Last date for receipt of tender formsSep 19, 2024Mar 12, 2025
Finalisation of buybackSep 25, 2024Mar 19, 2025
Last Date for settlment of bidsSep 26, 2024Mar 19, 2025
Last Date for extinguishment of sharesOct 08, 2024Apr 01, 2025

Financial Details and Other Relevent Information

Comparison of Aarti Drugs Buyback 2024 and Nava Limited Buyback 2025 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Aarti Drugs Ltd.Nava Ltd.
Financial

Aarti Drugs Ltd. Financial Information (Restated Consolidated)

Aarti Drugs Ltd.'s revenue decreased by -7% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 202231 Mar 2021
Assets2,421.42,207.961,766.01
Revenue2,532.612,718.252,499.962,159.31
Profit After Tax171.59166.36205280.4
Net Worth1,262.071,173.691,016.62
Amount in ₹ Crore

Nava Limited Financial Information (Restated Consolidated)

Period Ended31 Mar 202431 Mar 2023
Assets9,698.111,159.98
Revenue3,955.033,928
Profit After Tax1,255.321,220.17
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.95 500.05 529.89
Jun-2024 538.90 450.20 507.91
May-2024 508.85 453.60 483.92

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jan-2025 1016.40 823.60 917.55
Dec-2024 1069.95 962.70 1014.40
Nov-2024 1130.00 877.35 975.56
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.20 500.00 530.05
Jun-2024 538.95 451.05 508.13
May-2024 508.95 456.00 484.25

Compare with others

Compare:

Aarti Drugs Buyback 2024 and Nava Limited Buyback 2025